WuXi Biologics included in S&P Global Sustainability Yearbook (China) for fourth consecutive year
- Achieved a CSA score placing it in S&P Global’s Global Top 1% for the fourth consecutive year.
- Included in both the 2026 S&P Global Sustainability Yearbook and the Sustainability Yearbook (China Edition).
- China Edition considered 1,800 eligible companies and selected around 190 for inclusion.
- Holds multiple ESG recognitions, including MSCI AAA, EcoVadis Platinum, CDP “A List”, Sustainalytics negligible‑risk designation, and inclusion in FTSE4Good.
S&P Global recognition
WuXi Biologics was included in the 2026 S&P Global Sustainability Yearbook (China Edition) and the Global Sustainability Yearbook after achieving a Corporate Sustainability Assessment (CSA) score that places it in the Global Top 1% for the fourth consecutive year. The China Edition considered 1,800 eligible companies and ultimately selected around 190 for inclusion.
Company response
Dr. Chris Chen, WuXi Biologics CEO and Chair of the ESG Committee, said the selection reflects continued dedication to enhancing sustainability performance and reiterated the company’s commitment to collaborate with stakeholders and to provide end‑to‑end Green CRDMO solutions that empower clients and promote responsible practices across the value chain.
External endorsements
S&P Global’s Head of Corporate Solutions and Engagement acknowledged participating companies’ contributions to transparency and performance. WuXi Biologics also cites recognition from other ESG frameworks and indices, including MSCI AAA, EcoVadis Platinum, Dow Jones Best‑in‑Class listings, CDP “A List” for Climate Change, Water Security and Supplier Engagement, Sustainalytics’ highest negligible‑risk rating and industry/regional leader designations, FTSE4Good inclusion, ISS ESG “Prime”, and the Hang Seng Corporate Sustainability Benchmark.
Source: WuXi
